Mega Genomics Limited disclosed that on 28 July 2026 it repurchased 108,200 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 7.08 and HKD 7.10, for a total cash outlay of HKD 0.77 million. The volume-weighted average price was HKD 7.08 per share.

Following the transaction, the company’s outstanding share count (excluding treasury shares) fell from 223.64 million to 223.53 million, a reduction of 0.048 %. Treasury shares increased to 768,000, while total issued shares remained unchanged at 224.30 million because the repurchased shares have been retained in treasury rather than cancelled.

The buy-back forms part of the mandate approved on 21 May 2026, which authorises the company to repurchase up to 22.43 million shares. To date, 768,000 shares have been repurchased under this mandate, representing 0.34 % of the issued share capital authorised for buy-back at the mandate date.

In accordance with Hong Kong listing rules, Mega Genomics is subject to a 30-day moratorium on issuing new shares or selling treasury shares; the restriction extends through 28 August 2026.

All repurchases have been confirmed as compliant with the Listing Rules and other applicable regulations.